Nektar Therapeutics officer proposes $15.4K sale
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Nektar Therapeutics (NKTR) is named as issuer in a notice listing officer and director Robin Howard’s proposed sale of 429 common shares, with an aggregate market value of $15,378.49 and an approximate sale date of November 17, 2026. The shares were acquired through restricted stock vesting on November 13, 2026, as compensation. The notice says the sale includes an amount necessary to cover a tax obligation from settlement of a vested equity award distribution. It also lists a prior sale of 418 common shares on August 18, 2026, for gross proceeds of $30,086.93.
Key Figures
Key Terms
Restricted Stock Vesting financial
vested equity award distribution financial
Aggregate Market Value financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What reason is given for Robin Howard’s proposed NKTR sale?
AI-generated analysis. How Rhea-AI works. Not financial advice.